A study warns that patients regain part of the weight after stopping medications like Ozempic and Wegovy. Researchers from the University of Cambridge analyzed data from 3,200 people in six clinical trials, monitored for up to 52 weeks after treatment was suspended.
The results, published in EClinicalMedicine, indicate that on average patients regain part of the weight equivalent to 60% of what was lost during the use of these drugs. Although they generate reductions of 15% to 20% of body weight, the interruption causes a significant rebound in the first year. After 52 weeks, the weight stabilizes, maintaining a net loss of 25%.
For example, someone who loses 20% of their weight with the medication retains only 5% of that reduction a year later. This pattern highlights that patients regain part of the weight when the appetite-suppressing effect disappears.
How GLP-1 medications like Ozempic and Wegovy work
These drugs, GLP-1 receptor agonists, control blood sugar and reduce hunger. The researcher Brajan Budini explains that they limit appetite, leading to consuming fewer calories. When they are stopped, appetite returns, contributing to weight gain.
Reasons why not all weight is regained
The authors suggest that patients regain part of the weight but not all thanks to new habits acquired, such as smaller portions and balanced diets. Possible hormonal or brain changes that regulate hunger may persist.
Expert recommendations to avoid the rebound
- Incorporate nutritional guidance and exercise during treatment.
- Steven Luo, co-author, emphasizes evaluating risks of recovery before suspending.
- Global statistics show that 70% of those using GLP-1 long-term maintain moderate weight losses with lifestyle changes.
Historical context and warnings about Ozempic and Wegovy
Ozempic, initially approved for diabetes in 2017, and Wegovy for obesity in 2021, revolutionized weight control. However, previous trials like Novo Nordisk’s STEP already hinted at post-treatment rebounds. The FDA has warned about side effects like nausea, but the rebound concerns doctors. In 2025, sales exceeded $20 billion, fueling debates about pharmaceutical dependence.
Experts like the Endocrine Society recommend combining them with behavioral therapies so patients regain part of the weight minimally. This study warns the need for sustainable strategies, avoiding quick-fix illusions.
In summary, while patients regain part of the weight after stopping Ozempic and Wegovy, the 25% weight loss retained offers hope if lasting habits are adopted.
